Biomarkers of brain injury in cerebral infections

Clinical Chemistry

Volumn 60, Issue 6, 2014, Pages 823-834

  Rohlwink, Ursula K ^a   Figaji, Anthony A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MYELIN BASIC PROTEIN; NEURON SPECIFIC ENOLASE; PROTEIN S100B; TAU PROTEIN;

BRAIN INFECTION; BRAIN INJURY; CLINICAL RESEARCH; CLINICAL STUDY; EXPERIMENTAL STUDY; HUMAN; INJURY SEVERITY; PATHOPHYSIOLOGY; REFERENCE VALUE; REVIEW;

BIOLOGICAL MARKERS; BRAIN INJURIES; CENTRAL NERVOUS SYSTEM INFECTIONS; HUMANS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT;

EID: 84901745308     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.212472     Document Type: Review

References (76)

1. Hamed SA, Hamed EA, Zakary MM. Oxidative stress and S-100B protein in children with bacterial meningitis. BMC Neurol 2009;9:51.
2. Coyle PK. Overview of acute and chronic meningitis. Neurol Clin 1999;17:691-710. (Pubitemid 29517305)
3. Unden J, Christensson B, Bellner J, Alling C, Romner B. Serum S100B levels in patients with cerebral and extracerebral infectious disease. Scand J Infect Dis 2004;36:10-3. (Pubitemid 38219764)
4. Van Engelen BG, Lamers KJ, Gabreels FJ, Wevers RA, van Geel WJ, Borm GF. Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin Chem 1992;38:813-6.
5. Brand HK, Hermans PW, de Groot R. Host biomarkers and paediatric infectious diseases: from molecular profiles to clinical application. Adv Exp Med Biol 2010;659:19-31.
6. Koedel U, Klein M, Pfister HW. New understandings on the pathophysiology of bacterial meningitis. Curr Opin Infect Dis 2010;23:217-23.
7. Sellner J, Tauber M, Lieb S. Pathogeneis and pathophysiology of bacterial CNS infections. In: Roos KL Tunkel AR, eds. Bacterial infections of the central nervous system. New York: Elsevier; 2010. p 1-16.
8. (Handbook of clinical neurology; vol. 96, 3rd series).
9. Bonneh-Barkay D. Biomarkers of encephalitis. In: Hayasaka D, ed. Pathogenesis of encephalitis. Rijeka (Croatia): InTech; 2011. p 1-17.
10. Petzold A. CSF biomarkers for improved prognostic accuracy in acute CNS disease. Neurol Res 2007;29:691-708. (Pubitemid 350086068)
11. Berger RP. The use of serum biomarkers to predict outcome after traumatic brain injury in adults and children. J Head Trauma Rehabil 2006;21: 315-33. (Pubitemid 44258961)
12. Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci 1987; 10:269-95. (Pubitemid 17022775)
13. Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004;37:512-8. (Pubitemid 38845014)
14. Lewandrowski K, Chen A, Januzzi J. Cardiac markers for myocardial infarction. A brief review. Am J Clin Pathol 2002;118 Suppl:S93-9.
15. Kuhle J, Petzold A. What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases. Expert Opin Med Diagn 2011;5:333-46.
16. Lamers KJ, Vos P, Verbeek MM, Rosmalen F, van Geel WJ, van Engelen BG. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res Bull 2003;61: 261-4. (Pubitemid 36952472)
17. Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Esscher T, Påhlman S. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987;18:911-8. (Pubitemid 17126635)
18. Bakay RA, Ward AA Jr. Enzymatic changes in serum and cerebrospinal fluid in neurological injury. J Neurosurg 1983;58:27-37. (Pubitemid 13220944)
19. Lamers KJ, van Engelen BG, Gabreels FJ, Hommes OR, Borm GF, Wevers RA. Cerebrospinal neuronspecific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol Scand 1995;92:247-51.
20. Sandler SJ, Figaji AA, Adelson PD. Clinical applications of biomarkers in pediatric traumatic brain injury. Childs Nerv Syst 2010;26:205-13.
21. Lo TY, Jones PA, Minns RA. Pediatric brain trauma outcome prediction using paired serum levels of inflammatory mediators and brainspecific proteins. J Neurotrauma 2009;26:1479-87.
22. Berger RP, Beers SR, Richichi R, Wiesman D, Adelson PD. Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J Neurotrauma 2007;24:1793-801.
23. Wiesmann M, Missler U, Hagenstrom H, Gottmann D. S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta Neurochir 1997;139:1155-60. (Pubitemid 28014896)
24. Mokuno K, Kato K, Kawai K, Matsuoka Y, Yanagi T, Sobue I. Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases. J Neurol Sci 1983;60:443-51. (Pubitemid 13051195)
25. Sheng JG, Mrak RE, Rovnaghi CR, Kozlowska E, Van Eldik LJ, Griffin WS. Human brain S100 beta and S100 beta mRNA expression increases with age: pathogenic implications for Alzheimer's disease. Neurobiol Aging 1996;17:359-63. (Pubitemid 26200412)
26. Bottiger BW, Mobes S, Glatzer R, Bauer H, Gries A, Bartsch P, et al. Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation 2001;103:2694-8. (Pubitemid 32538784)
27. Lima JE, Takayanagui OM, Garcia LV, Leite JP. Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders. Braz J Med Biol Res 2004;37:19-26. (Pubitemid 38240140)
28. Teunissen CE, Tumani H, Bennett JL, Berven FS, Brundin L, Comabella M, et al. Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int 2011;2011:246412.
29. Butterfield LH, Potter DM, Kirkwood JM. Multiplex serum biomarker assessments: technical and biostatistical issues. J Transl Med 2011;9:173.
30. Warsinke A, Benkert A, Scheller FW. Electrochemical immunoassays. Fresenius J Anal Chem 2000; 366:622-34.
31. Gosling JP. A decade of development in immunoassay methodology. Clin Chem 1990;36(8 pt 1):1408-27.
32. Voller A, Bartlett A, Bidwell DE. Enzyme immunoassays with special reference to ELISA techniques. J Clin Pathol 1978;31:507-20. (Pubitemid 8358776)
33. Infante JR, Martinez A, Ochoa J, Canadillas F, Torres-Avisbal M, Vallejo JA, et al. Cerebrospinal fluid S-100 protein levels in neurological pathologies. J Physiol Biochem 2003;59:255-61.
34. Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci 2002;7:1356-68.
35. Steiner J, Bernstein HG, Bielau H, Berndt A, Brisch R, Mawrin C, et al. Evidence for a wide extraastrocytic distribution of S100B in human brain. BMC Neurosci 2007;8:2.
36. Raabe A, Seifert V. Protein S-100B as a serum marker of brain damage in severe head injury: preliminary results. Neurosurg Rev 2000;23: 136-8.
37. Raabe A, Seifert V. Fatal secondary increase in serum S-100B protein after severe head injury. Report of three cases. J Neurosurg 1999;91: 875-7. (Pubitemid 30053164)
38. Spinella PC, Donoghue A, Rajendra A, Drott HR, Dominguez TE, Helfaer M. Cerebrospinal fluid levels of S-100beta in children and its elevation in Research Funding: Clinical Infectious Diseases Research Initiative, Wellcome Trust grant. pediatric meningitis. Pediatr Crit Care Med 2004; 5:53-7.
39. Raabe A, Kopetsch O, Gross U, Zimmermann M, Gebhart P. Measurements of serum S-100B protein: effects of storage time and temperature on pre-analytical stability. Clin Chem Lab Med 2003;41:700-3. (Pubitemid 36722827)
40. Gazzolo D, Frulio R, Bruschettini P, Lituania M, Michetti F. Effects of temperature on preanalytical stability of S100B protein concentrations in urine of healthy full-term infants. Clin Chim Acta 2004;350:231-2. (Pubitemid 39458267)
41. Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997;28:1956-60. (Pubitemid 27459003)
42. Bertsch T, Casarin W, Kretschmar M, Zimmer W, Walter S, Sommer C, et al. Protein S-100B: a serum marker for ischemic and infectious injury of cerebral tissue. Clin Chem Lab Med 2001;39: 319-23. (Pubitemid 32433332)
43. Goncalves CA, Leite MC, Nardin P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 2008;41:755-63.
44. Wright NT, Inman KG, Levine JA, Cannon BR, Varney KM, Weber DJ. Refinement of the solution structure and dynamic properties of Ca(2+)-bound rat S100B. J Biomol NMR 2008;42:279-86.
45. Mazzini GS, Souza DO, Portela LV. The ischemic heart as an extracerebral source for S100B. Resuscitation 2009;80:144.
46. Tiu SC, Chan WY, Heizmann CW, Schafer BW, Shu SY, Yew DT. Differential expression of S100B and S100A6(1) in the human fetal and aged cerebral cortex. Brain Res Dev Brain Res 2000;119:159-68. (Pubitemid 30089806)
47. Gazzolo D, Bruschettini M, Corvino V, Oliva R, Sarli R, Lituania M, et al. S100b protein concentrations in amniotic fluid correlate with gestational age and with cerebral ultrasound scanning results in healthy fetuses. Clin Chem 2001;47: 954-6. (Pubitemid 32398055)
48. Gazzolo D, Vinesi P, Marinoni E, Di Iorio R, Marras M, Lituania M, et al. S100B protein concentrations in cord blood: correlations with gestational age in term and preterm deliveries. Clin Chem 2000;46:998-1000.
49. Portela LV, Tort AB, Schaf DV, Ribeiro L, Nora DB, Walz R, et al. The serum S100B concentration is age dependent. Clin Chem 2002;48(6 Pt 1): 950-2. (Pubitemid 34587601)
50. Gazzolo D, Michetti F, Bruschettini M, Marchese N, Lituania M, Mangraviti S, et al. Pediatric concentrations of S100B protein in blood: age- and sex-related changes. Clin Chem 2003;49:967-70. (Pubitemid 36623482)
51. Bouvier D, Castellani C, Fournier M, Dauphin JB, Ughetto S, Breton M, et al. Reference ranges for serum S100B protein during the first three years of life. Clin Biochem 2011;44:927-9.
52. Nygaard O, Langbakk B, Romner B. Age- and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder. Clin Chem 1997;43:541-3. (Pubitemid 27106494)
53. Wiesmann M, Missler U, Gottmann D, Gehring S. Plasma S-100b protein concentration in healthy adults is age- and sex-independent. Clin Chem 1998;44:1056-8. (Pubitemid 28213152)
54. Garnier Y, Frigiola A, Li Volti G, Florio P, Frulio R, Berger R, et al. Increased maternal/fetal blood S100B levels following systemic endotoxin administration and periventricular white matter injury in preterm fetal sheep. Reprod Sci 2009;16: 758-66.
55. Giussani DA, Thakor AS, Frulio R, Gazzolo D. Acute hypoxia increases S100beta protein in association with blood flow redistribution away from peripheral circulations in fetal sheep. Pediatr Res 2005;58:179-84. (Pubitemid 41099858)
56. Lins H, Wallesch CW, Wunderlich MT. Sequential analyses of neurobiochemical markers of cerebral damage in cerebrospinal fluid and serum in CNS infections. Acta Neurol Scand 2005;112:303-8. (Pubitemid 41530727)
57. Gazzolo D, Grutzfeld D, Michetti F, Toesca A, Lituania M, Bruschettini M, et al. Increased S100B in cerebrospinal fluid of infants with bacterial meningitis: relationship to brain damage and routine cerebrospinal fluid findings. Clin Chem 2004;50:941-4. (Pubitemid 38543677)
58. Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg 2005;103(1 Suppl):61-8. (Pubitemid 44954950)
59. Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RS, Ruppel RA, Kochanek PM. Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 2002;109:E31.
60. Nygaard O, Langbakk B, Romner B. Neuron-specific enolase concentrations in serum and cerebrospinal fluid in patients with no previous history of neurological disorder. Scand J Clin Lab Invest 1998;58:183-6. (Pubitemid 28308203)
61. Rodriguez-Nunez A, Cid E, Eiris J, Rodriguez-Garcia J, Camina F, Rodriguez-Segade S, Castro-Gago M. Neuron-specific enolase levels in the cerebrospinal fluid of neurologically healthy children. Brain Dev 1999;21:16-9. (Pubitemid 29073340)
62. Casmiro M, Maitan S, De Pasquale F, Cova V, Scarpa E, Vignatelli L; NSE Study Group. Cerebro-spinal fluid and serum neuron-specific enolase concentrations in a normal population. Eur J Neurol 2005;12:369-74. (Pubitemid 40524177)
63. Hardemark HG, Persson L, Bolander HG, Hillered L, Olsson Y, Pahlman S. Neuron-specific enolase is a marker of cerebral ischemia and infarct size in rat cerebrospinal fluid. Stroke 1988;19:1140-4.
64. Song TJ, Choi YC, Lee KY, Kim WJ. Serum and cerebrospinal fluid neuron-specific enolase for diagnosis of tuberculous meningitis. Yonsei Med J 2012;53:1068-72.
65. Bandyopadhyay S, Hennes H, Gorelick MH, Wells RG, Walsh-Kelly CM. Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury. Acad Emerg Med 2005;12:732-8. (Pubitemid 41021884)
66. Rodriguez-Nunez A, Cid E, Rodriguez-Garcia J, Camina F, Rodriguez-Segade S, Castro-Gago M. Neuron-specific enolase, nucleotides, nucleosides, purine bases, oxypurines and uric acid concentrations in cerebrospinal fluid of children with meningitis. Brain Dev 2003;25:102-6. (Pubitemid 36170305)
67. Nara T, Nozaki H, Nakae Y, Arai T, Ohashi T. Neuron-specific enolase in comatose children. Am J Dis Child 1988;142:173-4. (Pubitemid 18081258)
68. Tsukahara H, Fujii Y, Matsubara K, Yamada M, Nagaoka Y, Saito Y, et al. Prognostic value of brain injury biomarkers in acute encephalitis/ encephalopathy. Pediatr Int 2013;55:461-4.
69. Grahn A, Hagberg L, Nilsson S, Blennow K, Zetterberg H, Studahl M. Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. J Neurol 2013;260:1813-21.
70. Goonetilleke UR, Scarborough M, Ward SA, Gordon SB. Proteomic analysis of cerebrospinal fluid in pneumococcal meningitis reveals potential biomarkers associated with survival. J Infect Dis 2010;202:542-50.
71. Kataria J, Rukmangadachar LA, Hariprasad G, O J, Triapthi M, Srinivasan A. Two dimensional difference gel electrophoresis analysis of cerebrospinal fluid in tuberculous meningitis patients. J Proteomics 2011;74:2194-203.
72. Zhang A, Sun H, Wang P, Han Y, Wang X. Recent and potential developments of biofluid analyses in metabolomics. J Proteomics 2012;75:1079-88.
73. Coen M, O'Sullivan M, Bubb WA, Kuchel PW, Sorrell T. Proton nuclear magnetic resonance-based metabonomics for rapid diagnosis of meningitis and ventriculitis. Clin Infect Dis 2005;41: 1582-90. (Pubitemid 41691596)
74. Subramanian A, Gupta A, Saxena S, Gupta A, Kumar R, Nigam A, et al. Proton MR CSF analysis and a new software as predictors for the differentiation of meningitis in children. NMR Biomed 2005;18:213-25. (Pubitemid 40936441)
75. Townend W, Ingebrigtsen T. Head injury outcome prediction: a role for protein S-100B? Injury 2006; 37:1098-108. (Pubitemid 44765014)
76. Spinella PC, Dominguez T, Drott HR, Huh J, Mc-Cormick L, Rajendra A, et al. S-100beta protein-serum levels in healthy children and its association with outcome in pediatric traumatic brain injury. Crit Care Med 2003;31:939-45. (Pubitemid 36379608)